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Complex Aortic PathologiesThe management of aortic aneurysm has evolved consid-
erably over the last 20 years and few vascular surgeons in
1990 would have believed that within 25 years, aneurysm
treatment would be close to becoming a day case inter-
vention. Endovascular aortic aneurysm repair (EVAR) has
largely replaced open repair of infrarenal abdominal aortic
aneurysm (AAA) in anatomically suitable patients. This is
despite the fact that while multicentre randomized trials
revealed a clear survival advantage in the ﬁrst 30 days (and
again at 3 years), no late survival advantage favouring EVAR
has been demonstrated.1,2 Long-term surveillance after
EVAR has revealed high rates of late complications, neces-
sitating secondary and tertiary re-interventions. On reﬂec-
tion, many of these late technical failures probably
represent situations where anatomical suitability criteria
were not always respected or where the technique was
poorly planned and/or executed from the outset.3 In addi-
tion, one should bear in mind that aneurysmal disease is a
continuous pathological process. Early success does not
always translate into long-term durability, particularly
where the infrarenal aortic neck is subject to progressive
dilatation.4,5 If vascular surgeons want to strive for optimal
outcome, they have to respect anatomical restrictions for
device usage, while also anticipating the consequences of
disease progression (aortic neck dilatation, increasing iliac
tortuosity).
Following the success of EVAR in the treatment of
infrarenal AAA, innovative surgeons and industry developed
devices to achieve sealing in patients with more complex
aneurysms (juxtarenal, thoracoabdominal). Fenestrated
stent grafts expanded endovascular options for patients
with juxtarenal AAA and excellent results from high volume
centres have been published, but only after many years of
experimentation and device innovation.6e8
A recent overview comparing outcomes following open
surgery for chimney EVAR and fenestrated EVAR (F-EVAR) in
patients with complex AAA showed that F-EVAR was asso-
ciated with a peri-operative mortality of 2.4%, with high
rates of aneurysm exclusion and target vessel patency, while
late complications secondary to endoleaks and disease
progression were rare.9,10
F-EVAR is, however, a more complex endovascular
technique and requires a much higher level of expertise.1078-5884/$ e see front matter  2014 European Society for Vascular
Surgery. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2014.12.001Careful patient selection and detailed pre-operative plan-
ning are mandatory as any technical failure can lead to
serious complications, requiring extremely challenging
“bail-out” options. The importance of having an integrated
and fully functioning team cannot be underestimated.
These types of procedures should not be planned and
performed by solitary enthusiasts, no matter how moti-
vated or skilled they might be. “The modern endovascular
team” requires experienced nursing and operating
personnel, with expertise in three dimensional imaging,
anticipation of navigation difﬁculties, awareness of bail out
manoeuvres, and a high level of knowledge regarding stent
graft capabilities and limitations. Each of these parameters
is crucial for delivering optimal patient outcomes. In
addition, a hybrid endovascular suite providing perfect
imaging quality and access to advanced imaging applica-
tions, and a large stock of back up materials and ancillary
products is highly advisable.
Despite the ﬂourish of interest in F-EVAR and (more
recently) branched EVAR (B-EVAR), a recently published
paper clearly reiterates the need for strictly adhering to
case selection, meticulous procedural planning, and tech-
nical execution. Raux et al.11 compared F-EVAR with open
surgery in patients with complex AAA in two large volume
centres. In this study, F-EVAR had higher 30 day mortality
rates (9.5% vs. 2%), as well as higher procedural compli-
cations (24% vs. 7%) and graft related complications (30%
vs. 2%) than open surgery. The high mortality rates after
F-EVAR in this study are worrying and suggest that there
may be concerns about generalizability within less expe-
rienced centres. F-EVAR procedures were performed in
only one of the two centres, and only included 59 pro-
cedures that had been performed over a decade. The au-
thors conceded that “the learning curve of the
endovascular technique was likely to be responsible in part
for the adverse outcomes observed in the F-EVAR cohort”.
The authors reported no differences in cardiac, pulmonary,
and renal events between F-EVAR and open surgery. This,
therefore, raises the question whether the higher rate of
observed complications after F-EVAR were the result of
signiﬁcant intra-operative technical difﬁculties leading to
prolonged operative times, possibly because of poor
anatomical patient selection. In short, if one reserves F-
EVAR for only the most complex cases (where there will
not be the commensurate level of technical expertise for
dealing with complications) it should come as no surprise
when good results do not follow.
364 EditorialThe evolution of F-EVAR and (more recently) B-EVAR has
opened up the thoraco-abdominal aorta (TAAA) to endo-
vascular repair. This clearly represents another level of
technological complexity and, even in expert centres, mor-
tality rates of 10% have been reported, along with not
insigniﬁcant risks of paraplegia. Stent grafts for treating
TAAA have to be individually customized to each patient’s
anatomy and the required endovascular skills are much
more complex, with access being required via both the
upper and lower limbs. The logistical and organizational
requirements also become much higher in terms of hard-
ware (hybrid room mandatory) and software (back up ma-
terials of all kinds including a wide range of bridging stent
grafts).12
Patient selection is critical. Although it is now possible to
offer an endovascular solution to TAAA patients not suitable
for open surgery, experience suggests that ASA Type IV
patients do not do very well after TAAA branch grafting.13
Although the peri-procedural mortality rate in ASA IV pa-
tients was not signiﬁcantly higher, cumulative survival was
signiﬁcantly lower, suggesting that relatively few will beneﬁt
from the procedure.
Mortality rates in highly experienced centres are now
below 10% (17/218 [7.7%] for Nürnberg and 14/204 [6.9%]
for Lille), but some patients still died following intra-
operative technical failures (rupture, limb ischaemia,
mesenteric ischaemia, stroke).13,14 Without the required
organizational set up and experience, it is likely that other
studies will report inferior results, which could jeopardize
more widespread adoption of this technique. The WIN-
DOWS multicentre French Registry reported outcomes in
268 patients who received F-EVAR or B-EVAR for juxtarenal
AAA (group 1), suprarenal AAA and TAAA Type IV (group 2),
and TAAA Type I, II, III (group 3).15 In hospital mortality was
6.5% for group 1 patients, 14.3% for group 2, and 21.4% for
group 3. These increasing mortality rates probably reﬂect
the effect of a learning curve in the treatment of increas-
ingly complex aortic pathologies. Participating centres were
considered to be “expert centres” if they had a previous
experience of at least 15 F-EVAR/B-EVAR procedures. Prior
to enrolling patients, however, most centres only had
experience with F-EVAR procedures in juxtarenal AAA pa-
tients and only started their experience with more complex
cases during the trial. As mentioned earlier, lack of experi-
ence combined with the inclusion of high risk surgical pa-
tients with difﬁcult anatomies, inevitably results in bad
outcomes. The authors acknowledged that peri-operative
mortality and morbidity rates were signiﬁcantly inﬂuenced
by intra-operative technical complications and increased
procedural duration. This resulted in high rates of signiﬁcant
renal dysfunction and spinal cord ischaemia (SCI). SCI, for
example, affected 16.6% of patients with a TAAA Type I, II,
and III.
The incidence of SCI after branched TAAA repair can be
lower (than was observed in WINDOWS) through the use of
a “strict” multidisciplinary protocol.16 Pre-operative graft
planning should aim to preserve ﬂow in the left subclavian
artery and both internal iliac arteries as a priority, togetherwith pre-operative spinal catheter placement for cerebral
spinal ﬂuid (CSF) drainage. Intra- and post-operatively, the
anaesthetic team should aggressively correct any hypoten-
sive episodes, as well as monitor CSF drainage. Another
important factor is the need to restore pelvic and lower
limb perfusion as soon as possible. Use of an open approach
to femoral access vessels and encirclement of puncture sites
with purse string sutures is routine. This facilitates early
removal of introduction systems/sheaths, in order to rapidly
restore blood ﬂow to the pelvis and lower limbs. Apart from
reducing lower limb ischaemia time and reperfusion injury,
early blood ﬂow restoration to the lower limbs may also
have a positive impact on the prevention of SCI by
increasing collateral ﬂow and by reducing reperfusion
oedema around the spinal cord.17,18 Finally, a “staged
approach” (implantation of a thoracic endograft 4e6 weeks
prior to the F-EVAR/B-EVAR repair) also has the potential to
reduce the risk of paraplegia through arteriogenic pre-
conditioning. The “collateral network concept”, described by
Etz et al.,17 is based upon the principle of a remodelling
process driven by pressure gradients across paraspinal col-
laterals. Evidence suggests that staged repair signiﬁcantly
reduces paraplegia rates after extensive thoracoabdominal
aortic aneurysm repair.19
An “off the shelf” four branch graft is now available for
use in acute TAAA cases. However, there is a potential
downside in that some surgeons/interventionists may be
tempted to implant these devices in less than optimal
anatomical situations in order to avoid the 6 week delay,
which is otherwise necessary to manufacture custom made
devices. While compromise is understandable in life
threatening situations (e.g., rupture), advocating the use of
off the shelf devices in elective patients with inappropriate
anatomy will almost certainly jeopardize mid- and long-term
outcomes. Our initial experience with this new four branch
device is positive, but the need for additional materials and
ancillary products does increase, and it can be quite chal-
lenging to catheterize some of the target vessels because
anatomical vessel alignments are less than perfect.
In conclusion, the available evidence suggests that more
complex aortic endovascular procedures (especially
branched repair of TAAAs) should be focused within higher
volume institutions that can provide all treatment options,
have experience in dealing with technically challenging
intra-operative problems and where multidisciplinary
cooperation is such that the choice of treatment is not
inﬂuenced by specialty, political, or ﬁnancial aspects.20,21
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